Connect Biopharma Holdings Ltd

Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.

CNTB | US

Overview

Corporate Details

ISIN(s):: US2075231017
LEI:
Country:: United States of America
Address:: 3580 CARMEL MOUNTAIN ROAD, SUITE 200, 92130 SAN DIEGO
Website:: https://www.connectbiopharm.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Connect Biopharma Holdings Ltd. is a global, clinical-stage biopharmaceutical company dedicated to developing therapies for inflammatory diseases. The company focuses on the discovery and development of next-generation immune modulators designed to treat T cell-driven autoimmune and inflammatory conditions. Its clinical pipeline aims to transform care for patients with chronic diseases, including asthma and Chronic Obstructive Pulmonary Disease (COPD).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Connect Biopharma Holdings Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Connect Biopharma Holdings Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Connect Biopharma Holdings Ltd via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
KIORA PHARMACEUTICALS INC Developing advanced small molecule therapies for vision-threatening retinal diseases.	United States of America	KPRX
KISSEI PHARMACEUTICAL CO.,LTD. Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.	Japan	4547
Klaria Pharma Holding AB Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.	Sweden	KLAR
Klotho Neurosciences, Inc. Advancing gene and cell therapies for neurodegenerative disorders, cancer, and chronic diseases.	United States of America	KLTO
KOA SHOJI HOLDINGS CO.,LTD. Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.	Japan	9273
KOBAYASHI PHARMACEUTICAL CO.,LTD. Manufactures OTC pharma, personal care, and household goods for niche consumer markets.	Japan	4967
Kodiak Sciences Inc. Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.	United States of America	KOD
Kohjin Bio Co., Ltd. A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.	Japan	177A
KOLON LIFE SCIENCE Inc. Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.	South Korea	102940
Kolon TissueGene, Inc. Developing cell and gene therapies for orthopedic and degenerative disorders.	United States of America	950160